Mga Batayang Estadistika
| CIK | 882873 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Urologix, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 10, 2015 |
8-K 1 urologix1524508k.htm FORM 8-K DATED JULY 9, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): July 9, 2015 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Inc |
|
| July 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-28414 Urologix, Inc. (Exact name of registrant as specified in its chart |
|
| July 10, 2015 |
EX-99.1 2 urologix152450ex99-1.htm PRESS RELEASE DATED JULY 9, 2015 Exhibit 99.1 July 9, 2015 For Immediate Release Urologix Announces SEC Deregistration MINNEAPOLIS — July 9, 2015 — Urologix, Inc. (OTCQB: ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced its decision to terminate and suspend the registration of its stock with |
|
| May 29, 2015 |
SD 1 urologix151938sd.htm FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Urologix, Inc. (Exact name of the registrant as specified in its charter) Minnesota 0-28414 41-1697237 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 14405 21st Avenue North, Minnea |
|
| May 29, 2015 |
Conflict Minerals Report Urologix, Inc. 2014 Calendar Year Exhibit 1.01 Conflict Minerals Report Urologix, Inc. 2014 Calendar Year Unless otherwise defined in this Conflict Minerals Report, terms have the meanings ascribed to them in Rule 13p-1 under the Securities Exchange Act of 1934 (?Rule?), the instructions to Form SD, and the SEC Release relating to the Rule (Release No. 34-67716 dated August 22, 2012). (1) Due Diligence "Urologix,? "we," "our" and |
|
| May 14, 2015 |
Urologix FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2015 (Quarterly Report) 10-Q 1 urologix15174910q.htm FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tran |
|
| May 13, 2015 |
8-K 1 urologix1517378k.htm FORM 8-K DATED MAY 12, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 12, 2015 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Inc |
|
| May 13, 2015 |
Urologix, Inc. Statements of Operations (Unaudited, in thousands, except per-share data) EXHIBIT 99.1 May 12, 2015 For Immediate Release Urologix Reports Third Quarter Fiscal Year 2015 Results Recent Quarter Results ? Revenue $2.8 Million ? Ending cash balances, including restricted cash of $532,000 ? $2.8 million owed under the Prostiva license and Medtronic promissory note remains past due ? Cost-effectiveness of Urologix products being presented at 2015 American Urological Associat |
|
| March 23, 2015 |
8-K 1 urologix1511108k.htm FORM 8-K DATED MARCH 17, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 17, 2015 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of |
|
| March 23, 2015 |
EXHIBIT 99.1 March 23, 2015 For Immediate Release Urologix Announces Hiring of Chief Financial Officer MINNEAPOLIS - March 23, 2015 - Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the appointment of Scott M. Madson as its Chief Financial Officer effective April 1, 2015. Mr. Madson brings over 30 years |
|
| March 23, 2015 |
14405 21st Avenue South Minneapolis, MN 55447 March 17, 2015 EXHIBIT 10.2 14405 21st Avenue South Minneapolis, MN 55447 March 17, 2015 Dear Scott: Although your employment is ?at will? and may be terminated by you or Urologix at any time for any reason, Urologix has agreed to provide you with a particular severance pay benefit following a Change in Control in the event your employment is terminated without Cause, or by you for Good Reason. Terms not otherwi |
|
| March 23, 2015 |
EX-10.1 2 urologix151110ex10-1.htm LETTER AGREEMENT March 17, 2015 EXHIBIT 10.1 Mr. Scott Madson Re: Offer of Employment Dear Scott: On behalf of Urologix, Inc. (the “Company”), I am pleased to offer you the position of Chief Financial Officer. In this position, you would also serve as Urologix’ principal financial officer and principal accounting officer as those terms are defined under the rules |
|
| February 6, 2015 |
8-K 1 urologix1504398k.htm FORM 8-K DATED FEBRUARY 5, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 5, 2015 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdictio |
|
| February 6, 2015 |
Urologix, Inc. Statements of Operations (Unaudited, in thousands, except per share data) EXHIBIT 99.1 February 5, 2015 For Immediate Release Urologix Reports Second Quarter Fiscal Year 2015 Results Recent Quarter Highlights ● Revenue $3.1 Million, 2% increase from first quarter fiscal year 2015. ● Net loss reduced by 67% to $357,000 from a net loss of $1.1 million in the second quarter of fiscal year 2014 and 18% lower than first quarter net loss of $437,000. ● Total cash balances, in |
|
| January 12, 2015 |
EXHIBIT 99.1 January 12, 2015 For Immediate Release Urologix Reports Preliminary Fiscal Year 2015 Second Quarter Revenue and Cash Results • Second quarter preliminary revenue of $3.1M, up 2% sequentially MINNEAPOLIS —January 12, 2015— Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, announces preliminary revenue and ca |
|
| January 12, 2015 |
8-K 1 urologix1500848k.htm FORM 8-K DATED JANUARY 12, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 12, 2015 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdictio |
|
| November 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 6, 2014 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File N |
|
| November 5, 2014 |
Urologix, Inc. Statements of Operations (Unaudited, in thousands, except per share data) EXHIBIT 99.1 Urologix Reports First Quarter Fiscal Year 2015 Results Recent Quarter Highlights • Reduced operating expenses 44% compared to the first quarter of the prior year. • Net loss reduced by 67% to $437,000 from a net loss of $1,334,000 in the first quarter of the prior year. MINNEAPOLIS — November 4, 2014— Urologix®, Inc. (OTCQB: ULGX), the leading provider of in-office procedures for the |
|
| November 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 4, 2014 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File N |
|
| September 25, 2014 |
8-K 1 urologix1434468k.htm FORM 8-K DATED SEPTEMBER 22, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): September 22, 2014 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdi |
|
| September 23, 2014 |
ULGX / Urologix, Inc. DEF 14A - - DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| August 20, 2014 |
Urologix, Inc. Statements of Operations (Unaudited, in thousands, except per share data) Exhibit 99.1 August 19, 2014 For Immediate Release Urologix Reports Fourth Quarter and Fiscal Year 2014 Results Recent Highlights • Urologix restructured the company in April 2014 which reduced cash utilization in the fourth quarter to $98,000 • Cost-effectiveness data covering Cooled ThermoTherapyTM presented at 2014 AUA Annual Meeting in May MINNEAPOLIS — August 19, 2014— Urologix®, Inc. (OTCQB: |
|
| August 20, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 19, 2014 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Nu |
|
| August 19, 2014 |
8-K 1 urologix1430748k.htm FORM 8-K DATED AUGUST 13, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 13, 2014 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction |
|
| May 30, 2014 |
Conflict Minerals Report Urologix, Inc. 2013 Calendar Year Exhibit 1.01 Conflict Minerals Report Urologix, Inc. 2013 Calendar Year Unless otherwise defined in this Conflict Minerals Report, terms have the meanings ascribed to them in Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule”), the instructions to Form SD, and the SEC Release relating to the Rule (Release No. 34-67716 dated August 22, 2012). (1) Due Diligence "Urologix,” "we," "our" and |
|
| May 30, 2014 |
SD 1 urologix141990sd.htm FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Urologix, Inc. (Exact name of the registrant as specified in its charter) Minnesota 0-28414 41-1697237 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 14405 21st Avenue North, Minnea |
|
| May 7, 2014 |
Three Months Ended March 31, 2014 EX-99.1 2 urologix141724ex99-1.htm PRESS RELEASE DATED MAY 6, 2014 EXHIBIT 99.1 May 6, 2014 For Immediate Release Urologix Reports Fiscal Year 2014 Third Quarter Results • Third quarter revenue totaled $3.4 million • Cash balance of $816,000 as of March 31, 2014 • Annualized expenses reduced by over $4.0 million since January 1, 2014 MINNEAPOLIS, May 6, 2014 (GLOBE NEWSWIRE) - Urologix®, Inc. (OTC |
|
| May 7, 2014 |
8-K 1 urologix1417248k.htm FORM 8-K DATED MAY 6, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 6, 2014 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incor |
|
| April 16, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): April 10, 2014 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Num |
|
| April 16, 2014 |
April 10, 2014 For Immediate Release Urologix Announces Strategic Restructuring, Reports Preliminary Revenue and Cash Results for the Third Quarter of Fiscal Year 2014 • Third quarter revenue totaled $3. |
|
| March 27, 2014 |
8-K 1 urologix1411088k.htm FORM 8-K DATED MARCH 21, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 21, 2014 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of |
|
| March 27, 2014 |
EXHIBIT 10.1 [Medtronic Letterhead] March 21, 2014 Greg Fluet, Chief Executive Officer Urologix, Inc. 14405 21st Avenue North Minneapolis MN 55447 Re: Past due amounts under License Agreement dated September 6, 2011, as amended June 28, 2013 (the “License Agreement”). Capitalized terms used in this letter have the meaning given in the License Agreement. Dear Greg: As you are aware, payments due to |
|
| February 13, 2014 |
ULGX / Urologix, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - ULGX AS OF 12/31/2013 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* UROLOGIX INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 917273104 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is fil |
|
| February 13, 2014 |
Urologix FORM 10-Q FOR THE QUARTER ENDED DECEMBER 31, 2013 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED December 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File Number 0-28414 UROLOGIX, INC. (Exa |
|
| February 5, 2014 |
- FORM 8-K DATED FEBRUARY 4, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 4, 2014 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File N |
|
| February 5, 2014 |
Urologix, Inc. Statements of Operations (Unaudited, in thousands, except per share data) Exhibit 99.1 February 4, 2014 For Immediate Release Urologix Reports Fiscal Year 2014 Second Quarter Results · Second quarter revenue totaled $3.8 million MINNEAPOLIS, Feb. 4, 2014 (GLOBE NEWSWIRE) - Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fiscal second quarter ended De |
|
| February 4, 2014 |
8-K 1 urologix1404018k.htm FORM 8-K DATED JANUARY 30, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 30, 2014 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdictio |
|
| February 4, 2014 |
THIRD Amendment to Loan and security agreement EX-10.1 2 urologix140401ex10-1.htm THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT EXHIBIT 10.1 THIRD Amendment to Loan and security agreement THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into this 30th day of January, 2014 (“Closing Date”), by and between SILICON VALLEY BANK, a California corporation (“Bank”) and UROLOGIX, INC., a Minnesota corporation (“Borrow |
|
| January 10, 2014 |
8-K 1 urologix1400778k.htm FORM 8-K DATED JANUARY 9, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 9, 2014 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction |
|
| January 10, 2014 |
SECOND Amendment to Loan and security agreement EX-10.1 2 urologix14007710-1.htm SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT EXHIBIT 10.1 SECOND Amendment to Loan and security agreement THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into this 9th day of January, 2014 (the “Closing Date”), by and between SILICON VALLEY BANK, a California corporation (“Bank”) and UROLOGIX, INC., a Minnesota corporation (“Bo |
|
| January 8, 2014 |
8-K 1 urologix1400478k.htm FORM 8-K DATED JANUARY 8, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 8, 2014 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction |
|
| January 8, 2014 |
EX-99.1 2 urologix140047ex99-1.htm PRESS RELEASE ISSUED JANUARY 8, 2014 EXHIBIT 99.1 January 8, 2014 For Immediate Release Urologix Announces Strategic Restructuring, Reports Preliminary Revenue and Cash Results for the Second Quarter of Fiscal Year 2014 • Second quarter revenue totaled $3.8 million, up 1% sequentially • Cash balance of $1.3M as of December 31, 2013 MINNEAPOLIS — January 8, 2014— |
|
| November 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 28, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (C |
|
| November 8, 2013 |
FIRST AMENDMENT OF THE LICENSE AGREEMENT EX-10.5 2 urologix134662ex10-5.htm FIRST AMENDMENT OF THE LICENSE AGREEMENT EXHIBIT 10.5 FIRST AMENDMENT OF THE LICENSE AGREEMENT This First Amendment of the License Agreement (the “First Amendment”) is dated as of June 28, 2013 (the “First Amendment Date”), by and among Medtronic, Inc., a Minnesota corporation (“Medtronic”), Medtronic VidaMed, Inc., a Delaware corporation and wholly-owned subsidi |
|
| November 8, 2013 |
8-K 1 urologix1346698k.htm FORM 8-K DATED NOVEMBER 7, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 7, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdictio |
|
| November 8, 2013 |
ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION OF UROLOGIX, INC. EX-3.1 2 urologix134669ex3-1.htm ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION EXHIBIT 3.1 ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION OF UROLOGIX, INC. The undersigned, an officer of Urologix, Inc., a Minnesota corporation, in order to amend the Articles of Incorporation of Urologix, Inc. hereby states as follows: The following amendment to Article III of the Articles of Incorporation |
|
| October 30, 2013 |
Urologix, Inc. Certain Remarks of Brian J. Smrdel 1st Quarter FY 2014 Earnings Call October 29, 2013 EX-99.2 3 urologix134521ex99-2.htm STATEMENTS OF BRIAN J. SMRDEL Exhibit 99.2 Urologix, Inc. Certain Remarks of Brian J. Smrdel 1st Quarter FY 2014 Earnings Call October 29, 2013 First quarter fiscal year 2014 revenue totaled $3.8 million, down 9.7% sequentially from the fourth quarter of fiscal year 2013 and down 4.8% compared to the first quarter of fiscal year 2013. The sequential decrease in r |
|
| October 30, 2013 |
Urologix, Inc. Statements of Operations (Unaudited, in thousands, except per share data) EX-99.1 2 urologix134521ex99-1.htm PRESS RELEASE ISSUED OCTOBER 29, 2013 Exhibit 99.1 October 29, 2013 For Immediate Release Urologix Reports Fiscal Year 2014 First Quarter Results Executive Summary • First quarter revenue totaled $3.8 million, down 4.8% year-over-year. • Reaffirms fiscal year 2014 total revenue guidance in the range of $15 million to $17 million. MINNEAPOLIS — October 29, 2013— U |
|
| October 30, 2013 |
8-K 1 urologix1345218k.htm FORM 8-K DATED OCTOBER 29, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): October 29, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdictio |
|
| October 10, 2013 |
ULGX / Urologix, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - ULGX AS OF 09/30/2013 Passive Investment SC 13G/A 1 ulgx13gasep13.htm ULGX AS OF 09/30/2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* UROLOGIX INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 917273104 (CUSIP Number) September 30, 2013 (Date of Event which Requires Filing of Statement) Check the appropriate box to desig |
|
| September 27, 2013 |
- DEFINITIVE ADDITIONAL MATERIALS DEFA14A 1 urologix133982defa14a.htm DEFINITIVE ADDITIONAL MATERIALS *** Exercise Your Right to Vote *** Important Notice Regarding the Availability of Proxy Materials for the B A R C O D E Shareholder Meeting to Be Held on November 07, 2013 Meeting Information UROLOGIX, INC. Meeting Type: Annual Meeting For holders as of: September 19, 2013 Date: November 07, 2013 Time: 4:00 PM CST Location: Shera |
|
| September 27, 2013 |
DEF 14A 1 urologix133982def14a.htm DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, fo |
|
| September 6, 2013 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| August 21, 2013 |
8-K 1 urologix1336338k.htm FORM 8-K DATED AUGUST 20, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 20, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction |
|
| August 21, 2013 |
Urologix, Inc. Statements of Operations (Unaudited, in thousands, except per share data) EX-99.1 2 urologix133633ex99-1.htm PRESS RELEASE DATED AUGUST 20, 2013 EXHIBIT 99.1 August 20, 2013 For Immediate Release Urologix Reports Fourth Quarter and Fiscal Year 2013 Results Executive Summary • Fiscal year 2013 revenue totaled $16.6 million in-line with the Company’s fiscal year guidance range of $16.0 million to $17.0 million. • Fourth quarter revenue totaled $4.2 million, up 2.5% sequen |
|
| August 20, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 14, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Nu |
|
| July 5, 2013 |
EXHIBIT 10.3 SECURITY AGREEMENT THIS SECURITY AGREEMENT (the “Agreement”) is made as of June 28, 2013, by and between UROLOGIX, INC., a Minnesota corporation (the “Debtor”), and MEDTRONIC, INC., a Minnesota corporation (the “Lender”). BACKGROUND A. The Lender is making certain financial accommodations pursuant to that certain Promissory Note (the “Note”) dated as of the date hereof made by the Deb |
|
| July 5, 2013 |
8-K 1 urologix1331028k.htm FORM 8-K DATED JUNE 28, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 28, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of I |
|
| July 5, 2013 |
EXHIBIT 10.2 THE HOLDER’S RIGHTS HEREUNDER ARE SUBORDINATE TO THE RIGHTS OF SILICON VALLEY BANK (“SENIOR LENDER”) AS SET FORTH IN THAT CERTAIN SUBORDINATION AGREEMENT DATED AS OF THE DATE HEREOF BY AND AMONG THE BORROWER, THE HOLDER AND THE SENIOR LENDER, AS MAY BE AMENDED FROM TIME TO TIME. THE HOLDER’S RIGHTS HEREUNDER MAY ALSO BE SUBJECT TO OTHER SUBORDINATION AGREEMENTS AS PROVIDED HEREIN. PRO |
|
| July 5, 2013 |
EX-99.1 7 urologix133102ex99-1.htm PRESS RELEASE DATED JULY 1, 2013 EXHIBIT 99.1 July 1st, 2013 For Immediate Release Urologix Announces Restructuring of Payment Obligations to Medtronic and Reports Preliminary Fiscal Year 2013 Revenue and Cash Results MINNEAPOLIS —July 1, 2013— Urologix®, Inc. (OTCQB:ULGX), the leading provider of in-office BPH therapy, announces the restructuring of payment obli |
|
| July 5, 2013 |
FIRST AMENDMENT OF THE TRANSITION SERVICES AND SUPPLY AGREEMENT EX-10.4 5 urologix133102ex10-4.htm FIRST AMENDMENT TO TRANSITION SERVICES AND SUPPLY AGREEMENT EXHIBIT 10.4 FIRST AMENDMENT OF THE TRANSITION SERVICES AND SUPPLY AGREEMENT This First Amendment of the Transition Services and Supply Agreement (the “First Amendment”) is effective as of March 1, 2013 (the “First Amendment Date”), by and among Medtronic, Inc., a Minnesota corporation (“Licensor”), and |
|
| July 5, 2013 |
RESTRUCTURING AGREEMENT AND AMENDMENT TO TRANSACTION DOCUMENTS EX-10.1 2 urologix133102ex10-1.htm RESTRUCTURING AGREEMENT AND AMENDMENT TO TRANSACTION DOCUMENTS EXHIBIT 10.1 RESTRUCTURING AGREEMENT AND AMENDMENT TO TRANSACTION DOCUMENTS This RESTRUCTURING AGREEMENT AND AMENDMENT TO TRANSACTION DOCUMENTS (the “Agreement”) is entered into as of the 28th day of June, 2013, by and among Medtronic, Inc., a Minnesota corporation (“Medtronic”), Medtronic VidaMed, In |
|
| July 5, 2013 |
FIRST AMENDMENT OF THE LICENSE AGREEMENT EX-10.5 6 urologix133102ex10-5.htm FIRST AMENDMENT OF LICENSE AGREEMENT EXHIBIT 10.5 CERTAIN INFORMATION INDICATED BY [ * * * ] HAS BEEN DELETED FROM THIS EXHIBIT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24b-2. FIRST AMENDMENT OF THE LICENSE AGREEMENT This First Amendment of the License Agreement (the “First Amendm |
|
| June 5, 2013 |
EXHIBIT 99.1 June 5, 2013 For Immediate Release Urologix to Transfer from NASDAQ to the OTCQB Marketplace MINNEAPOLIS —June 5, 2013— Urologix®, Inc. (NASDAQ:ULGX), the leading provider of in-office BPH therapy, announced today that its Board of Directors has authorized the transfer of the Company’s common stock from The NASDAQ Capital Market (“NASDAQ”) to OTC Markets Group’s OTCQB Marketplace (“OT |
|
| June 5, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 5, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Numbe |
|
| May 23, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 21, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Numbe |
|
| May 2, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 1, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Number |
|
| May 2, 2013 |
Urologix, Inc. Certain Remarks of Brian J. Smrdel 3rd Quarter FY 2013 Earnings Call May 1, 2013 EX-99.2 3 urologix132125ex99-2.htm REMARKS OF BRIAN J. SMRDEL AT TELEPHONE CONFERENCE HELD ON MAY 1, 2013 Exhibit 99.2 Urologix, Inc. Certain Remarks of Brian J. Smrdel 3rd Quarter FY 2013 Earnings Call May 1, 2013 • Q3 sales of CTT were $2.661 million, down $191,000 compared to the last quarter, or 6.7%, and also down $355,000, or 11.8%, compared to last year. Q3 Prostiva revenue of $1.421 millio |
|
| May 2, 2013 |
Urologix, Inc. Statements of Operations (Unaudited, in thousands, except per share data) EX-99.1 2 urologix132125ex99-1.htm PRESS RELEASE DATED MAY 1, 2013 Exhibit 99.1 May 1, 2013 For Immediate Release Urologix Reports Fiscal Year 2013 Third Quarter Results and Reaffirms Annual Guidance Third Quarter Summary • Third quarter revenue of $4.1 million • Quarter-end cash balance of $5.1 million • Guidance for fiscal year 2013 revenue reaffirmed at $16.0 million to $17.0 million MINNEAPOLI |
|
| April 18, 2013 |
- FORM 8-K DATED APRIL 16, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): April 16, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Num |
|
| April 18, 2013 |
EX-99.1 2 urologix131828ex99-1.htm PRESS RELEASE DATED APRIL 17, 2013 EXHIBIT 99.1 April 17, 2013 For Immediate Release Urologix Receives Extension from NASDAQ to Regain Compliance with Listing Requirements MINNEAPOLIS —April 17, 2013— Urologix®, Inc. (NASDAQ:ULGX), the leading provider of in-office BPH therapy, announced today that the NASDAQ Hearings Panel (the "Panel") of The NASDAQ Stock Marke |
|
| April 8, 2013 |
EX-99.1 2 urologix131648ex99-1.htm PRESS RELEASE DATED APRIL 8, 2013 EXHIBIT 99.1 April 8, 2013 For Immediate Release Urologix Announces Important Milestone in Prostiva® RF Therapy Licensing Agreement MINNEAPOLIS — April 8, 2013— Urologix, Inc. (NASDAQ:ULGX), the leading provider of in-office BPH therapy, today announced that it has reached an important milestone in its licensing agreement with Me |
|
| April 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): April 8, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Numb |
|
| March 6, 2013 |
- FORM 8-K DATED FEBRUARY 28, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 28, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File |
|
| March 6, 2013 |
EX-16.1 2 urologix131043ex16-1.htm LETTER TO SECURITIES AND EXCHANGE COMMISSION Exhibit 16.1 March 6, 2013 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Urologix, Inc. and, under the date of September 21, 2012, we reported on the financial statements of Urologix, Inc. as of and for the years ended June 30, 2012 and 2011 |
|
| February 6, 2013 |
Urologix, Inc. Statements of Operations (Unaudited, in thousands, except per share data) Exhibit 99.1 February 5, 2013 For Immediate Release Urologix Reports Fiscal Year 2013 Second Quarter Results and Reaffirms Annual Guidance Executive Summary Second quarter revenue reported at $4.4 million, up 9.7% sequentially. Guidance for fiscal year 2013 revenue reaffirmed at $16.0 million to $17.0 million. MINNEAPOLIS — February 5, 2013— Urologix®, Inc. (NASDAQ:ULGX), the leading provider of i |
|
| February 6, 2013 |
ULGX / Urologix, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - ULGX AS OF 12/31/12 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* UROLOGIX INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 917273104 (CUSIP Number) December 31, 2012 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is fil |
|
| February 6, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 5, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File N |
|
| February 6, 2013 |
Urologix, Inc. Certain Remarks of Brian J. Smrdel 2nd Quarter FY 2013 Earnings Call February 5, 2013 EX-99.2 3 urologix130489ex99-2.htm CERTAIN REMARKS OF BRIAN J. SMRDEL, CFO Exhibit 99.2 Urologix, Inc. Certain Remarks of Brian J. Smrdel 2nd Quarter FY 2013 Earnings Call February 5, 2013 · [For the second quarter of fiscal 2013] Revenue for CTT grew by $247,000, or 9.5% and Prostiva revenue grew by $137,000, also up 10% sequentially but off of a smaller base. · On a year-over-year basis, our U.S |
|
| January 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 25, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File N |
|
| January 30, 2013 |
EXHIBIT 99.1 January 30, 2013 For Immediate Release Urologix Names Greg Fluet as New CEO MINNEAPOLIS — January 30, 2013 — Urologix®, Inc. (NASDAQ:ULGX), the leading provider of in-office BPH therapy, announced today that its Board of Directors has appointed Greg Fluet as the company’s Chief Executive Officer, effective immediately. He has also been elected to the Company’s Board of Directors. Mr. |
|
| January 29, 2013 |
Urologix Receives NASDAQ Notification Related to Minimum Bid Price Requirement EXHIBIT 99.1 January 29, 2013 For Immediate Release Contact Name: Brian Smrdel Phone Number: 763-475-7696 Email Address: [email protected] Urologix Receives NASDAQ Notification Related to Minimum Bid Price Requirement MINNEAPOLIS — January 29, 2013 — Urologix®, Inc. (NASDAQ:ULGX), the leading provider of in-office BPH therapy, announced today that it received a letter from The NASDAQ Stock Mark |
|
| January 29, 2013 |
8-K 1 urologix1303298k.htm FORM 8-K DATED JANUARY 23, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 23, 2013 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdictio |
|
| December 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 UROLOGIX, INC. (Exact name of registrant as specified in its charter) Minnesota 41-1697237 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 14405 21st Avenue North Minneapolis, Minnesota 55447 (Address of princip |
|
| December 6, 2012 |
- FORM 8-K DATED NOVEMBER 30, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 30, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File |
|
| December 6, 2012 |
FIRST Amendment to Loan and security agreement EXHIBIT 10.1 FIRST Amendment to Loan and security agreement THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into this 30th day of November, 2012 (“Closing Date”), by and between SILICON VALLEY BANK, a California corporation (“Bank”) and UROLOGIX, INC., a Minnesota corporation (“Borrower”). Recitals A. Bank and Borrower have entered into that certain Loan and Secur |
|
| November 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 20, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File |
|
| November 27, 2012 |
UROLOGIX, INC. 14405 21st Avenue North Minneapolis, MN 55447 November 20, 2012 EX-10.1 2 urologix124906ex10-1.htm LETTER AGREEMENT BETWEEN UROLOGIX, INC. AND STRYKER WARREN, JR. DATED NOVEMBER 20, 2012 Exhibit 10.1 UROLOGIX, INC. 14405 21st Avenue North Minneapolis, MN 55447 November 20, 2012 Mr. Stryker Warren, Jr. 14405 21st Avenue North Minneapolis, MN 55447 Dear Stryker: This letter outlines our agreement regarding a change in your role with Urologix, Inc. (“Urologix”) a |
|
| November 27, 2012 |
Urologix Announces Leadership Change EX-99.1 3 urologix124906ex99-1.htm PRESS RELEASE DATED NOVEMBER 20, 2012 Exhibit 99.1 FOR IMMEDIATE RELEASE Urologix Announces Leadership Change MINNEAPOLIS, Nov. 20, 2012 (GLOBE NEWSWIRE) - Urologix®, Inc. (ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced a leadership change. The company’s Chief Operating Officer Greg Fluet |
|
| November 19, 2012 |
- FORM 8-K DATED NOVEMBER 16, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): November 16, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File |
|
| October 5, 2012 |
DEF 14A 1 urologix124094s1def14a.htm DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Co |
|
| August 27, 2012 |
Urologix, Inc. Certain Remarks of Brian J. Smrdel 4th Quarter FY 2012 Earnings Call August 23, 2012 EX-99.2 3 urologix123485ex99-2.htm CERTAIN REMARKS AT TELEPHONE CONFERENCE Exhibit 99.2 Urologix, Inc. Certain Remarks of Brian J. Smrdel 4th Quarter FY 2012 Earnings Call August 23, 2012 · [International sales of Prostiva represent] only 4-5% of our total Company sales on an annualized basis [for fiscal year 2012]. · Third party mobile operations represent approximately 10% of fiscal year 2012 sa |
|
| August 27, 2012 |
Urologix Reports Results for Fourth Quarter and Fiscal Year 2012 Exhibit 99.1 FOR IMMEDIATE RELEASE Urologix Reports Results for Fourth Quarter and Fiscal Year 2012 Fiscal year 2012 revenue increased 35% over the fiscal year 2011 period in line with annual guidance Fourth quarter revenue of $4.5 million up 54% year-over-year and down 5% sequentially Positive cash flow in the fourth quarter of $42,000 Completion of secondary offering on August 7, 2012 raised $3. |
|
| August 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 23, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Nu |
|
| August 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 10, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Nu |
|
| August 9, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): August 7, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Num |
|
| August 9, 2012 |
Urologix Announces Closing of Over-Allotment Option EX-99.1 2 urologix123274ex99-1.htm PRESS RELEASE DATED AUGUST 7, 2012 EXHIBIT 99.1 FOR IMMEDIATE RELEASE Urologix Announces Closing of Over-Allotment Option MINNEAPOLIS — August 7, 2012 — Urologix®, Inc. (NASDAQ:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the sale of an additional 780,000 shares of its common stock at a |
|
| July 24, 2012 |
8-K 1 urologix1230488k.htm FORM 8-K DATED JULY 23, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): July 23, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of I |
|
| July 17, 2012 |
8-K 1 urologix1229728k.htm FORM 8-K DATED JULY 17, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): July 17, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of I |
|
| July 10, 2012 |
ULGX / Urologix, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - ULGX AS OF 06/30/2012 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* UROLOGIX INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 917273104 (CUSIP Number) June 30, 2012 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [ |
|
| July 5, 2012 |
Urologix Announces Closing of Follow-On Offering Exhibit 99.2 FOR IMMEDIATE RELEASE Urologix Announces Closing of Follow-On Offering MINNEAPOLIS — July 5, 2012 — Urologix®, Inc. (NASDAQ:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the closing of its previously announced follow-on firm commitment underwritten public offering of 5,200,000 shares of its common stock at a p |
|
| July 5, 2012 |
Urologix Announces Pricing of Follow-On Offering of 5,200,000 Shares of Common Stock Exhibit 99.1 FOR IMMEDIATE RELEASE Urologix Announces Pricing of Follow-On Offering of 5,200,000 Shares of Common Stock MINNEAPOLIS — June 29, 2012 — Urologix®, Inc. (NASDAQ:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the pricing of its registered follow-on firm commitment underwritten public offering of 5,200,000 shares |
|
| July 5, 2012 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): June 29, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Numb |
|
| June 29, 2012 |
Urologix, Inc. 5,200,000 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-181716 PROSPECTUS Urologix, Inc. 5,200,000 Shares of Common Stock We are offering 5,200,000 shares of our common stock. Our common stock is traded on the Nasdaq Capital Market under the symbol “ULGX.” The last reported sale price of our common stock on June 28, 2012 was $0.91 per share. Investing in our common stock involves a |
|
| June 22, 2012 |
[ ] Shares UROLOGIX, INC. Common Stock ($0.01 par value per Share) UNDERWRITING AGREEMENT Exhibit 1.1 [ ] Shares UROLOGIX, INC. Common Stock ($0.01 par value per Share) UNDERWRITING AGREEMENT [ ], 2012 DOUGHERTY & COMPANY LLC 90 South 7th Street, Suite 4300 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Urologix, Inc., a Minnesota corporation (the “Company”), proposes to issue and sell to Dougherty & Company LLC, a Delaware limited liability company (the “Underwriter”), [ ] shares |
|
| June 22, 2012 |
As filed with the Securities and Exchange Commission on June 22, 2012. Registration No. 333-181716 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 Registration Statement Under The Securities Act of 1933 UROLOGIX, INC. (Exact name of registrant as specified in its charter) Minnesota 3845 41-1697237 (State or other jurisdiction of incorporation or |
|
| June 13, 2012 |
FWP 1 urologix122534fwp.htm FORM FWP The issuer, Urologix, Inc., has filed with the Securities and Exchange Commission (the “SEC”) a registration statement, including a preliminary prospectus (the "Preliminary Prospectus"), for the offering to which this communication relates. Delivery of this communication has been preceded by, or is accompanied with, a copy of the Preliminary Prospectus. Before |
|
| June 8, 2012 |
Table of Contents As filed with the Securities and Exchange Commission on June 8, 2012. |
|
| June 7, 2012 |
ULGX / Urologix, Inc. / Blueline Partners, L.l.c. - SCHEDULE 13D/A #2 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Urologix, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 917273104 (CUSIP Number) Scott A. Shuda BlueLine Partners, LLC 319 Diablo Road, Suite 200 Danville, California 94506 (Name, Address and Telephone Number of Person Authorized to Receive Notices |
|
| May 25, 2012 |
Registration Statement - FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on May 25, 2012. |
|
| May 1, 2012 |
- FORM 8-K DATED APRIL 30, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): April 30, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Num |
|
| April 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): April 26, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Num |
|
| April 27, 2012 |
EX-99.2 3 urologix121883ex99-2.htm Q&A PORTION OF EARNINGS CONFERENCE CALL EXHIBIT 99.2 Question-and-Answer Portion of Urologix, Inc. Earnings Conference Call Relating to the Quarter Ended March 31, 2012 April 26, 2012 Q: My question is: your current ratio now is negative for the first time, although your cash flow is positive for this quarter just because of the deferred payments, what’s going to |
|
| April 27, 2012 |
Urologix Reports 59% Increase in Revenue Year-Over-Year for Fiscal 2012 Third Quarter EX-99.1 2 urologix121883ex99-1.htm PRESS RELEASE DATED APRIL 26, 2012 EXHIBIT 99.1 FOR IMMEDIATE RELEASE Urologix Reports 59% Increase in Revenue Year-Over-Year for Fiscal 2012 Third Quarter $4.7 million in total revenue, up 2% sequentially Positive cash flow in the quarter of $285 thousand Full year 2012 revenue guidance between $17.0 to $17.5 million MINNEAPOLIS — April 26, 2012 — Urologix®, Inc |
|
| April 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): April 19, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Num |
|
| April 25, 2012 |
[Urologix letterhead] April 23, 2012 EX-10.1 2 urologix12182810-1.htm AMENDED AND RESTATED LETTER AGREEMENT Exhibit 10.1 [Urologix letterhead] April 23, 2012 Dear []: Although your employment is “at will” and may be terminated by you or Urologix at any time for any reason, Urologix has agreed to provide you with a particular severance pay benefit following a Change in Control in the event your employment is terminated without Cause, |
|
| February 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 10, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File |
|
| January 25, 2012 |
8-K 1 urologix1202998k.htm FORM 8-K DATED JANUARY 24, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 24, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdictio |
|
| January 25, 2012 |
Urologix Reports 48% Increase in Sequential Revenue for Fiscal 2012 Second Quarter Exhibit 99.1 FOR IMMEDIATE RELEASE Urologix Reports 48% Increase in Sequential Revenue for Fiscal 2012 Second Quarter $4.7 million in revenue, 40% quarterly revenue growth year over year Positive cash flow in the quarter of $17 thousand $2 million credit facility established MINNEAPOLIS — January 24, 2012 — Urologix®, Inc. (NASDAQ:ULGX), the leading provider of in-office procedures for the safe, d |
|
| January 17, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 11, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File N |
|
| January 17, 2012 |
EX-10.1 2 urologix120192ex10-1.htm LOAN AND SECURITY AGREEMENT EXHIBIT 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of January 11, 2012 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and UROLOGIX, INC., a Minnesota corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower s |
|
| January 17, 2012 |
Urologix Secures $2 Million Credit Facility EX-99.1 3 urologix120192ex99-1.htm PRESS RELEASE ISSUED JANUARY 12, 2012 EXHIBIT 99.1 FOR IMMEDIATE RELEASE Urologix Secures $2 Million Credit Facility MINNEAPOLIS, MN - January 12, 2012 - Urologix, Inc. (NASDAQ: ULGX), the market leading medical device company for in-office procedures to treat BPH that provide safe, durable and effective results, today announced that it has secured a $2 million c |
|
| January 9, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 6, 2012 Urologix, Inc. (Exact name of Registrant as Specified in its Charter) Minnesota (State Or Other Jurisdiction Of Incorporation) 000-28414 41-1697237 (Commission File Nu |
|
| January 9, 2012 |
Urologix Regains Nasdaq Minimum Bid Price Requirement EX-99.1 2 urologix120085ex99-1.htm PRESS RELEASE ISSUED JANUARY 6, 2012 Exhibit 99.1 FOR IMMEDIATE RELEASE Urologix Regains Nasdaq Minimum Bid Price Requirement MINNEAPOLIS, MN - January 6, 2012 - Urologix, Inc. (NASDAQ: ULGX), is the market leading medical device company for in-office procedures to treat BPH that provide safe, durable and effective results. Urologix provides urologist customers t |
